Review: Allogeneic HCT for Diffuse Large B Cell Lymphoma

In this review article, the authors note that despite overall improvements in outcomes of patients with diffuse large B cell lymphoma (DLBCL), approximately 30-40% will develop relapsed or refractory disease. They outline a new algorithm intended to discriminate which relapsed and refractory DLBCL patients are most likely to benefit from autologous HCT versus allogeneic HCT, and which allogeneic HCT candidates would benefit most from reduced-intensity conditioning and which should receive myeloablative conditioning. They conclude that a prospective registry-based study is needed to define the optimal position of allogeneic HCT in the overall treatment strategy for DLBCL.

Klyuchnikov E, et al. Bone Marrow Transplant